Eli Lilly and Company $LLY Stock: Signal Advisors Wealth LLC Increases Position

Signal Advisors Wealth LLC grew its stake in Eli Lilly and Company (NYSE:LLY) by 13.6% during the third quarter, HoldingsChannel reports. The firm owned 12,708 shares of the company’s stock after purchasing an additional 1,517 shares during the quarter. Signal Advisors Wealth LLC’s holdings in Eli Lilly and Company were worth $14,705,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of LLY. BlackRock Inc. lifted its holdings in shares of Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after purchasing an additional 1,046,558 shares during the period. State Street Corp increased its stake in Eli Lilly and Company by 1.7% in the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after buying an additional 605,752 shares during the period. Bank of America Corp DE acquired a new position in Eli Lilly and Company in the 2nd quarter valued at $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Eli Lilly and Company by 1.9% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock worth $8,647,153,000 after buying an additional 137,364 shares during the last quarter. Finally, Jennison Associates LLC raised its position in Eli Lilly and Company by 7.9% during the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock worth $6,550,587,000 after buying an additional 400,538 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the subject of several recent analyst reports. TD Cowen restated a “buy” rating and issued a $1,250.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, September 22nd. Bank of America boosted their price target on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Wells Fargo & Company boosted their price target on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Cantor Fitzgerald increased their price target on shares of Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the stock an “overweight” rating in a report on Thursday, October 8th. Finally, Sanford C. Bernstein raised their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research report on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,313.43.

Eli Lilly and Company Trading Down 1.3%

Shares of LLY stock opened at $1,167.01 on Wednesday. The business’s fifty day moving average price is $1,176.60 and its 200 day moving average price is $1,102.08. The firm has a market capitalization of $1.10 trillion, a PE ratio of 39.16, a P/E/G ratio of 1.52 and a beta of 0.46. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. Eli Lilly and Company has a 1-year low of $783.85 and a 1-year high of $1,292.65.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The company had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same quarter last year, the company earned $6.31 earnings per share. Eli Lilly and Company’s quarterly revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 34.79 EPS for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In related news, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $15,958,170 in the last ninety days. 0.14% of the stock is currently owned by company insiders.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Erste Group raised its Eli Lilly earnings estimates to $36.55 per share for fiscal 2026 and $47.30 for 2027, modestly above its prior forecasts and the current consensus, signaling continued confidence in the company’s earnings momentum. Erste Group earnings estimates
• Positive Sentiment: Analysts continue to highlight Lilly’s rapid revenue and profit growth, supported by strong demand for diabetes and weight-loss medicines. Recent commentary suggests the company could raise its revenue outlook, while RBC reiterated an “outperform” rating and a $1,500 price target. Lilly growth and analyst outlook
• Positive Sentiment: Investors are focused on retatrutide, Lilly’s next-generation obesity candidate, which could potentially become a larger growth driver than Zepbound if clinical results support its efficacy and commercial viability. The company reports earnings on October 29, with updates on retatrutide likely to attract more attention than the quarterly results themselves. Retatrutide and upcoming earnings
• Positive Sentiment: Lilly is collaborating with Prelude Therapeutics on a Phase 1 breast-cancer trial evaluating PRT13722 with Verzenio and Inluriyo. Enrollment is expected to begin in the fourth quarter of 2026, adding another potential pipeline opportunity, although the program remains early stage. Prelude collaboration
• Neutral Sentiment: A Phase 3b study of Taltz combined with Zepbound showed improved skin clearance and weight loss in adults with plaque psoriasis and obesity, potentially supporting broader use of Lilly’s medicines, though the data are not yet a major revenue contributor. Taltz and Zepbound trial
• Negative Sentiment: Shares have pulled back amid profit-taking after a major run-up and concerns that Lilly’s premium valuation leaves less room for execution mistakes. The stock trades near record levels at roughly 39 times earnings, making upcoming guidance and pipeline updates especially important. Lilly stock pullback
• Negative Sentiment: A combination treatment produced more weight loss than Zepbound alone but also had substantially higher discontinuation rates, raising questions about tolerability and the eventual commercial potential of next-generation obesity therapies. Weight-loss combination study

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.